Safety and Immunogenicity of Cell-based Quadrivalent Influenza Vaccine: A Randomized Trial
Safety and immunogenicity of cell-based quadrivalent inactivated influenza vaccine is comparable to US-licensed vaccine indicated for use in children 6 month of age and older.